Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study

0
2544
In this lebrikizumab study in patients with skin of color and moderate-to-severe atopic dermatitis (AD), lebrikizumab improved signs and symptoms of AD and confirmed its favorable safety profile.
[American Journal of Clinical Dermatology]
Full Article